Nevertheless, prophylaxis remains the cornerstone of care for patients diagnosed with ICL.[17] New approaches to treatment have also included work with Interleukin- 2 (IL- 2 ) to increase the CD4+ lymphocyte count.[21, 22]. The gene discussed is IL2; the disease is idiopathic CD4 lymphocytopenia.